

Lupin launches Ophthalmic Suspension for Inflammation in US

The drug is indicated for the treatment of steroid-responsive inflammatory conditions such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, among others.



Mumbai: Lupin Limited (Lupin) has announced the launch of Loteprednol Etabonate Ophthalmic Suspension, in the United States.

The ophthalmic suspension is bioequivalent to Lotemax,

marketed by Bausch & Lomb Inc.

The drug is indicated for the treatment of steroid-responsive inflammatory conditions such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitis etc.

It is also indicated for the treatment of post-operative inflammation following ocular surgery.

According to IQVIA estimates as of May 2025, the drug reported annual sales of \$55 million (around ₹460 crore) in the US

News Source:

<https://pharma.economictimes.indiatimes.com/news/drug-approvals-and-launches/lupin-launches-new-ophthalmic-suspension-in-the-us-for-inflammation-treatment/122577288>